The US National Institutes of Health (NIH) has finalised an agreement to licence 11 Covid-19 technologies to the Medicines Patent Pool (MPP) through the WHO’s Covid-19 Technology Access Pool (C-TAP).

The move was announced by the US Government during the second Global Covid-19 Summit.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The technologies include SARS-CoV-2 stabilised spike protein, early-stage vaccine and diagnostic candidates, and research tools to support the development of vaccines and therapeutics.

According to WHO, the list includes RNASEH-assisted detection assay for RNA, detection of SARS-CoV-2 and other RNA virus, and a high-throughput diagnostic test.

The global and non-exclusive licences will help manufacturers to collaborate with MPP and C-TAP to use the technologies to make Covid-19 diagnosis and treatment available for people living in low- and middle-income countries.

See Also:

WHO director-general Dr Tedros Adhanom Ghebreyesus said: “I welcome the generous contribution NIH has made to C-TAP and its example of solidarity and sharing.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Whether it’s today’s pandemic or tomorrow’s health emergency, it’s through sharing and empowering lower-income countries to manufacture their own health tools that we can ensure a healthier future for everyone.”

NIH acting director Lawrence A Tabak said: “NIH scientists have developed innovative Covid-19 research tools, vaccines and diagnostics. While NIH cannot commercialise these early-stage technologies, we can share our knowledge wherever feasible to support our global partners.”

In 2020, WHO launched C-TAP to support swift, equitable and affordable access to Covid-19 health products. MPP holds the licences of the products.

Last year, C-TAP and MPP finalised a licencing agreement with the Spanish National Research Council (CSIC) for its Covid-19 serological antibody test.